15.10
-0.12 (-0.79%)
| 前收盘价格 | 15.22 |
| 收盘价格 | 14.75 |
| 成交量 | 634,923 |
| 平均成交量 (3个月) | 1,228,479 |
| 市值 | 1,552,929,408 |
| 价格/销量 (P/S) | 15.96 |
| 股市价格/股市净资产 (P/B) | 2.97 |
| 52周波幅 | |
| 利润日期 | 8 Apr 2026 |
| 营业利益率 (TTM) | -340.67% |
| 稀释每股收益 (EPS TTM) | -2.60 |
| 季度收入增长率 (YOY) | 11.30% |
| 总债务/股东权益 (D/E MRQ) | 5.54% |
| 流动比率 (MRQ) | 6.26 |
| 营业现金流 (OCF TTM) | -191.72 M |
| 杠杆自由现金流 (LFCF TTM) | -106.56 M |
| 资产报酬率 (ROA TTM) | -31.08% |
| 股东权益报酬率 (ROE TTM) | -64.16% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 看涨 | 混合的 |
| Biotechnology (全球的) | 看涨 | 混合的 | |
| 股票 | Nurix Therapeutics, Inc. | 看涨 | 看涨 |
AIStockmoo 评分
| 分析师共识 | 5.0 |
| 内部交易活动 | NA |
| 价格波动 | -2.0 |
| 技术平均移动指标 | -2.5 |
| 技术振荡指标 | -2.0 |
| 平均 | -0.38 |
|
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Core |
| 内部持股比例 | 1.41% |
| 机构持股比例 | 111.85% |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 36.00 (Morgan Stanley, 138.41%) | 购买 |
| 中 | 31.00 (105.30%) | |
| 低 | 26.00 (Needham, 72.19%) | 购买 |
| 平均值 | 31.63 (109.47%) | |
| 总计 | 8 购买 | |
| 平均价格@调整类型 | 17.72 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| BTIG | 29 Jan 2026 | 30.00 (98.68%) | 购买 | 17.59 |
| HC Wainwright & Co. | 29 Jan 2026 | 32.00 (111.92%) | 购买 | 17.59 |
| Needham | 29 Jan 2026 | 26.00 (72.19%) | 购买 | 17.59 |
| Piper Sandler | 29 Jan 2026 | 35.00 (131.79%) | 购买 | 17.59 |
| RBC Capital | 29 Jan 2026 | 30.00 (98.68%) | 购买 | 17.59 |
| Stifel | 29 Jan 2026 | 35.00 (131.79%) | 购买 | 17.59 |
| Wells Fargo | 29 Jan 2026 | 29.00 (92.05%) | 购买 | 17.59 |
| Morgan Stanley | 08 Jan 2026 | 36.00 (138.41%) | 购买 | 18.63 |
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合